Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.amjcard.2020.06.055 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Potential Role of Left Atrial Strain to Predict Atrial Fibrillation Recurrence after Catheter Ablation Therapy: A Clinical and Systematic Review.
J Cardiovasc Dev Dis
June 2024
Department of Medical Biotechnologies, Division of Cardiology, University of Siena, Policlinico "Le Scotte", 53100 Siena, Italy.
Pulmonary vein isolation (PVI) with catheter ablation (CA) represents an effective therapy for atrial fibrillation (AF). Unfortunately, it is still not exempt from severe complications. The balance of risks and benefits should be assessed, and a patient-tailored approach is desirable.
View Article and Find Full Text PDFOral anticoagulation after atrial fibrillation catheter ablation: benefits and risks.
Eur Heart J
February 2024
Department of Public Health, Health Management and Policy, Nara Medical University, Kashihara, Nara, Japan.
Article Synopsis
- The study investigates whether patients should continue oral anticoagulant (OAC) therapy after undergoing catheter ablation (CA) for atrial fibrillation (AF), analyzing outcomes based on the CHADS2 score.
- Data was collected from a Japanese nationwide database, covering patients who had CA for AF from April 2014 to March 2021, focusing on thromboembolic and bleeding events after 6 months.
- The results indicate that while 71% of patients continued OAC therapy after 6 months, the benefits and risks varied based on the CHADS2 score—higher scores showed fewer thromboembolic events but increased risk of major bleeding.
Clinical outcomes in elderly atrial fibrillation patients at increased bleeding risk treated with very low dose vs. regular-dose non-vitamin K antagonist oral anticoagulants: a nationwide cohort study.
Eur Heart J Cardiovasc Pharmacother
December 2023
Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK.
Aims: The Edoxaban Low-Dose for Elder Care Atrial Fibrillation Patients (ELDERCARE-AF) trial showed that edoxaban at a very low dosage (VLD) of 15 mg/day was more effective than a placebo at preventing stroke/systemic embolism without significantly increasing the risk of serious bleeding. We aimed to compare the effectiveness and safety for VLD non-vitamin K antagonist oral anticoagulants (NOACs) [edoxaban 15 mg o.d.
View Article and Find Full Text PDFSystematic Review and Meta-Analysis of Direct Oral Anticoagulants Versus Warfarin in Atrial Fibrillation With Low Stroke Risk.
Am J Cardiol
October 2023
Department of Cardiology, Changi General Hospital, Singapore. Electronic address:
Pivotal trials comparing direct oral anticoagulants (DOACs) against warfarin in patients with atrial fibrillation (AF) predominantly involved patients with high stroke risk. This study aimed to evaluate the efficacy and safety of DOAC versus warfarin in patients with low stroke risk. An online literature search was conducted to retrieve studies comparing clinical outcomes between patients treated with DOAC versus warfarin for AF, reporting outcomes for patients at low or minimal risk of stroke (CHADS-VASc scores ranging from 0 to 2 or CHADS scores ranging from 0 to 1).
View Article and Find Full Text PDF5-year stroke rates in nonvalvular atrial fibrillation after watchman compared to direct oral anticoagulants.
J Cardiol
March 2024
Department of Neurosurgery, University of Illinois at Chicago, Chicago, IL, USA.
Background: The WATCHMAN device (Boston Scientific; Marlborough, MA, USA) is noninferior to warfarin in preventing ischemic strokes while reducing bleeding risks associated with long term anticoagulation in nonvalvular atrial fibrillation (AFib). The device's performance compared to direct oral anticoagulants (DOAC) is less well known.
Objective: To compare 5-year major bleeding and ischemic stroke rates in patients with nonvalvular AFib who received a WATCHMAN device or DOAC therapy after a major bleeding event.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!